Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2024-02-26
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- Xencor, Inc.
- Target Recruit Count
- 212
- Registration Number
- NCT06276491
- Locations
- 🇺🇸
The Ohio State University, Columbus, Ohio, United States
🇺🇸Karmanos Cancer Institute, Detroit, Michigan, United States
🇺🇸The John Theruer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, United States
Study of Vudalimab or Pembrolizumab in Combination With Chemotherapy as First-line Treatment in Patients With Advanced NSCLC
- Conditions
- Interventions
- First Posted Date
- 2023-12-15
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- Xencor, Inc.
- Target Recruit Count
- 168
- Registration Number
- NCT06173505
- Locations
- 🇺🇸
Memorial Cancer Institute at Memorial Hospital West, Pembroke Pines, Florida, United States
🇺🇸Midwestern Regional Medical Center, Zion, Illinois, United States
🇬🇷Athens Medical Center, Athens, Greece
Multiple Ascending-Dose Study of XmAb®27564 in Patients With Psoriasis or Atopic Dermatitis
- Conditions
- Interventions
- First Posted Date
- 2023-08-22
- Last Posted Date
- 2024-05-16
- Lead Sponsor
- Xencor, Inc.
- Target Recruit Count
- 128
- Registration Number
- NCT06005792
- Locations
- 🇺🇸
Driven Research, Coral Gables, Florida, United States
🇺🇸Unison Clinical Trials, Sherman Oaks, California, United States
🇺🇸Clinical Trials Research Institute, Thousand Oaks, California, United States
A Study of XmAb®662 as Monotherapy or in Combination With Pembrolizumab in Advanced Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2023-08-18
- Last Posted Date
- 2024-08-23
- Lead Sponsor
- Xencor, Inc.
- Target Recruit Count
- 7
- Registration Number
- NCT05996445
- Locations
- 🇺🇸
Icahn School of Medicine at Mount Sinai, New York, New York, United States
🇺🇸Sarah Cannon Research Institute at HealthONE, Denver, Colorado, United States
🇺🇸University Of Virginia Comprehensive Cancer Center, Charlottesville, Virginia, United States
Phase 1, First-in-human, Dose-finding and Expansion Study to Evaluate XmAb®808 in Combination With Pembrolizumab in Advanced Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2022-10-18
- Last Posted Date
- 2024-04-25
- Lead Sponsor
- Xencor, Inc.
- Target Recruit Count
- 220
- Registration Number
- NCT05585034
- Locations
- 🇺🇸
Froedtert Hospital & The Medical College of Wisconsin, Milwaukee, Wisconsin, United States
🇺🇸Columbia University Irvine Medical Center, New York, New York, United States
🇺🇸UCLA Hematology/Oncology, Los Angeles, California, United States
Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma
- First Posted Date
- 2022-06-27
- Last Posted Date
- 2024-06-20
- Lead Sponsor
- Xencor, Inc.
- Target Recruit Count
- 95
- Registration Number
- NCT05433142
- Locations
- 🇺🇸
Memorial Sloan Kettering, New York, New York, United States
🇺🇸Columbia University Medical Center, New York, New York, United States
🇺🇸Department of Medical Oncology and Therapeutics Research, City of Hope, Duarte, California, United States
Phase 2 Study of Plamotamab Combined With Tafasitamab Plus Lenalidomide Versus Tafasitamab Plus Lenalidomide in Relapsed or Refractory (R/R) Diffuse Large-cell B-cell Lymphoma (DLBCL)
- Conditions
- Interventions
- First Posted Date
- 2022-04-14
- Last Posted Date
- 2024-04-30
- Lead Sponsor
- Xencor, Inc.
- Target Recruit Count
- 3
- Registration Number
- NCT05328102
- Locations
- 🇺🇸
Swedish Cancer Center, Seattle, Washington, United States
🇫🇷CHU de Rennes - Hopital de Pontchaillou, Rennes Cedex, France
🇪🇸Hospital Universitario Virgen de las Nieves, Granada, Spain
A Study of XmAb20717 (Vudalimab)in Patients With Selected Advanced Gynecologic and Genitourinary Malignancies
- Conditions
- Interventions
- First Posted Date
- 2021-09-02
- Last Posted Date
- 2024-02-02
- Lead Sponsor
- Xencor, Inc.
- Target Recruit Count
- 150
- Registration Number
- NCT05032040
- Locations
- 🇺🇸
Arizona Oncology Associates, PC - NAHOA, Prescott, Arizona, United States
🇺🇸Rocky Mountain Cancer Centers, Aurora, Colorado, United States
🇺🇸Medical Oncology Hematology Consultants, PA, Newark, Delaware, United States
XmAb®20717 (Vudalimab) Alone or in Combination With Chemotherapy or Targeted Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2021-08-13
- Last Posted Date
- 2024-10-11
- Lead Sponsor
- Xencor, Inc.
- Target Recruit Count
- 85
- Registration Number
- NCT05005728
- Locations
- 🇺🇸
Alaska Oncology and Hematology, Anchorage, Alaska, United States
🇺🇸Palo Verde Hematology Oncology, Glendale, Arizona, United States
🇺🇸Rocky Mountain Cancer Centers, Lone Tree, Colorado, United States
Safety, Tolerability and PK of a Single Subcutaneous Injection of XmAb27564 in Healthy Volunteers
- First Posted Date
- 2021-04-23
- Last Posted Date
- 2023-03-01
- Lead Sponsor
- Xencor, Inc.
- Target Recruit Count
- 48
- Registration Number
- NCT04857866
- Locations
- 🇺🇸
ICON Early Phase Services, LLC, San Antonio, Texas, United States